Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| May 26, 2020 | Director, Chairman & CEO | Bona fide gift | Form 4 | 30,000 | -- | 909,941 | |
| Oct 03, 2018 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 30,000 | $12.69 | 20,724,424 | |
| Jun 19, 2017 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 30,000 | $10.00 | 94,184 | |
| Jun 19, 2017 | Chief Medical Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 30,000 | $10.00 | 64,184 | |
| Jun 09, 2016 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 | |
| Mar 03, 2014 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 30,000 | -- | 111,969 | |
| Jul 09, 2012 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 | |
| Jun 13, 2012 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 | |
| Jan 19, 2011 | SVP, Business Operations | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 | |
| Jan 19, 2011 | VP, Technical Operations | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.